Emergent Biosolutions Inc EBS

NYS: EBS | ISIN: US29089Q1058   18/07/2025
6,930 USD (-4,81%)
(-4,81%)   18/07/2025
Grafiek Emergent Biosolutions Inc Grafiek Emergent Biosolutions Inc

Emergent Biosolutions Inc in het nieuws

16 oktober 2023 · Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic · Persbericht

22 augustus 2023 · Kenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600 · Persbericht

23 november 2021 · SiTime Set to Join S&P MidCap 400; Emergent BioSolutions to Join S&P SmallCap 600 · Persbericht

18 juni 2021 · EMERGENT BIOSOLUTIONS 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Emergent BioSolutions Inc. - EBS · Persbericht

14 juni 2021 · EBS Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors or June 18, 2021 Deadline in Securities Fraud Class Action Lawsuit · Persbericht

8 juni 2021 · Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. · Persbericht

2 juni 2021 · Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. · Persbericht

28 mei 2021 · Kessler Topaz Meltzer & Check, LLP: Reminds Investors of Securities Fraud Class Action Filed Against Emergent BioSolutions Inc. · Persbericht

23 mei 2021 · DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Emergent BioSolutions Inc. Securities Fraud Class Action Lawsuit · Persbericht

17 mei 2021 · Kessler Topaz Meltzer & Check, LLP Files A Shareholder Class Action Lawsuit Against Emergent Biosolutions Inc. (NYSE: EBS) For Violations Of Federal Securities Laws With Expanded Class Period · Persbericht

Profiel Emergent Biosolutions Inc

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: emergentbiosolutions.com

Hoofdzetel: Gaithersburg, Maryland vlag Verenigde Staten

CEO: Robert Kramer

Werknemers: 2.607

Mijn selecties